References1 Concha JSS, Pena S, Gaffney RG et al.; Skin Myositis Delphi Group. Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. Br J Dermatol 2020; 182: 410-7. 2 Concha JSS, Tarazi M, Kushner CJ et al. The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria. Br J Dermatol 2019; 180:1001-8. 3 Lundberg IE, Tj€ arnlund A, Bottai M et al.; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol 2017; 69:2271-82. 4 Patel B, Khan N, Werth VP. Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease. J Am Acad Dermatol 2018; 79:77-83.e1. 5 Gerami P, Schope JM, McDonald L et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. References 1 Kim HS, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci 2018; 33:e213. 2 Suvarna VR. Real world evidence (RWE)are we (RWE) ready? Perspect Clin Res 2018; 9:61-3. 3 de Wijs LEM, Bosma AL, Erler NS et al. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol 2020; 182:418-26. 4 Simpson EL, Bieber T, Guttman-Yassky E et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335-48.